Results of a phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study).

Authors :: George, Thomas J.
Rogers, Sherise C.
Nassour, Ibrahim
Sahin, Ilyas
Ramnaraign, Brian Hemendra
Fabregas, Jesus
Hitchcock, Kathryn
Lin, Tuo
Liu, Gonghao
Zlotecki, Robert
Kayaleh, Omar Roger
Turk, Anita Ahmed
Fan, Z. Hugh
Russell, Karen Bullock
DeRemer, David L.
Lee, Ji-Hyun
Hughes, Steven J.
Source :: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p655-655, 117p
Publication Year :: 2024

Full Text Access

Tools